Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Top Page
Enlivex
(NASDAQ:ENLV)
36Underperform
Positive Factors
Financial Performance
Enlivex reported its 2Q24 financial results, closing the period with $25.9M in cash and short-term deposits.
Regulatory Approvals
The Danish Medicines Agency has authorized the initiation of the Phase 2 stage of the company’s multi-country Phase 1/2 trial in moderate and severe knee osteoarthritis (OA) patients.
Negative Factors
Financial Loss
The company recorded a 2Q24 net loss of $0.16 per share, moderately narrower than the forecast for a net loss of $0.22 per share.
Enlivex (ENLV) vs. S&P 500 (SPY)
Market Cap
$25.51M
Dividend YieldN/A
Average Volume (3M)170.47K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS Growth32.42%
CountryUS
Employees49
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.99
Shares Outstanding21,989,536
10 Day Avg. Volume418,144
30 Day Avg. Volume170,467
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Enlivex Business Overview & Revenue Model
Company DescriptionEnlivex (ENLV) is a clinical-stage immunotherapy company focused on developing innovative approaches to modulating the immune system. The company operates in the biotechnology sector, concentrating on the research and development of cell therapies for treating life-threatening immune-mediated diseases. Enlivex's core product is Allocetra, a proprietary cell therapy designed to restore balance to the immune system.
How the Company Makes MoneyEnlivex makes money primarily through the development and commercialization of its therapeutic candidates, particularly Allocetra. The company's revenue model is based on successful clinical trials leading to regulatory approvals, which would enable them to market and sell their therapies. Additionally, Enlivex may generate revenue through strategic partnerships, collaborations with pharmaceutical companies, and licensing agreements that provide upfront payments, milestone payments, and royalties on product sales. However, as a clinical-stage company, Enlivex is still in the process of establishing consistent revenue streams as it advances its therapies through clinical trials.
Enlivex Financial Statement Overview
Summary
Enlivex is facing challenges typical of early-stage biotechnology firms, with no revenue and ongoing losses. The firm needs to address its lack of revenue generation and improve cash flow management to ensure its financial viability. While the low debt offers some flexibility, the continuous cash burn and equity decline may limit future strategic options.Income Statement
Enlivex has faced significant operational challenges with no reported revenue in recent periods, leading to negative gross and net margins. The consistent negative EBIT and EBITDA margins highlight ongoing profitability issues, with a lack of revenue growth exacerbating the financial strain.15
Very Negative
Balance Sheet
The balance sheet reflects a relatively low debt-to-equity ratio, indicating limited leverage. However, the company's equity position has weakened over time as liabilities approach total assets, reducing the equity ratio. The declining stockholders' equity is a concern for financial stability.40
Negative
Cash Flow
Cash flow analysis reveals negative operating and free cash flows, indicating operational inefficiencies and cash burn. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow from operations, posing a risk to long-term sustainability.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 2.28M | 0.00 | Gross Profit |
| -548.00K | -835.00K | -777.00K | -546.00K | 1.99M | -297.00K | EBIT |
| -16.15M | -29.39M | -25.80M | -19.29M | -9.79M | -8.62M | EBITDA |
| -15.44M | -28.22M | -25.02M | -18.74M | -9.50M | -9.08M | Net Income Common Stockholders |
| -18.93M | -29.07M | -42.41M | -9.65M | -13.86M | -10.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 9.78M | 27.32M | 48.12M | 84.13M | 35.71M | 12.01M | Total Assets |
| 11.03M | 36.83M | 67.64M | 95.15M | 40.36M | 17.56M | Total Debt |
| 0.00 | 1.03M | 4.85M | 617.00K | 203.00K | 123.00K | Net Debt |
| -9.74M | 219.00K | -42.98M | -10.59M | -5.47M | -3.83M | Total Liabilities |
| 1.33M | 6.75M | 10.80M | 10.11M | 4.87M | 6.28M | Stockholders Equity |
| 9.71M | 30.08M | 56.84M | 85.04M | 35.49M | 11.28M |
| Cash Flow | Free Cash Flow | ||||
| -8.99M | -23.76M | -32.08M | -19.17M | -12.03M | -7.23M | Operating Cash Flow |
| -13.95M | -23.52M | -23.95M | -17.54M | -11.01M | -7.04M | Investing Cash Flow |
| 9.80M | -25.97M | 62.52M | -38.41M | -20.98M | -6.36M | Financing Cash Flow |
| 5.19M | 360.00K | 150.00K | 60.98M | 33.08M | 8.31M |
Enlivex Technical Analysis
Positive
1.20
Price Trends
1.12
Positive
1.19
Positive
1.28
Negative
Market Momentum
0.02
Negative
59.39
Neutral
66.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Positive. The current price of 1.2 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 1.12, and below the 200-day MA of 1.28, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 59.39 is Neutral, neither overbought nor oversold. The STOCH value of 66.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENLV.
Enlivex Risk Analysis
Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enlivex Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
45 Neutral | $6.95M | ― | -30.36% | ― | ― | 86.52% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
44 Neutral | $425.63M | ― | -54.15% | ― | ― | ― | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
41 Neutral | $62.62M | ― | 41.08% | ― | -0.55% | 49.85% | |
36 Underperform | $25.51M | ― | -57.93% | ― | ― | 32.42% |
* Healthcare Sector Average
Performance Comparison
ENLV
Enlivex
1.20
-3.10
-72.09%
BLUE
Bluebird Bio
3.86
-23.94
-86.12%
KPTI
Karyopharm Therapeutics
7.53
-13.77
-64.65%
ADAP
Adaptimmune Therapeutics
0.46
-1.13
-71.07%
ALLO
Allogene Therapeutics
2.06
-2.82
-57.79%
CYCN
Cyclerion Therapeutics
2.55
-0.46
-15.28%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.